ライフサイエンスコーパス: telithromycin

1 f hepatic toxicity for causal attribution to telithromycin.

2 or probable in their causal association with telithromycin.

3 mparable activity to the commercial ketolide telithromycin.

4 in, and a cladinose-containing derivative of telithromycin.

5 216 strains were found to be susceptible to telithromycin.

6 The current alternative telithromycin (1) from the newer ketolide class of macro

7 Telithromycin (2) is a third-generation macrolide antibi

8 e total synthesis of (-)-4,8,10-tridesmethyl telithromycin (3) wherein methyl groups have been replac

9 , the first lipopeptide in clinical use, and telithromycin, a ketolide that is derived from clarithro

10 The first cases of hepatotoxicity with telithromycin, a new class of ketolide antibiotic, were

11 and CO(2)) were used to test the activity of telithromycin against 110 erythromycin-susceptible and 1

12 gher probability, while the effectiveness of telithromycin against the A2058G mutation is explained b

13 ores during the treatment period was 1.3 for telithromycin and 1.0 for placebo (mean difference, -0.3

14 rly twofold increases for clarithromycin and telithromycin and a greater than threefold increase for

15 sistant to two different types of ketolides, telithromycin and ABT-773, but increased slightly the se

16 oach information on the interactions between telithromycin and the 50S ribosome was obtained.

17 xes with the known antibiotics linezolid and telithromycin, as well as with a new, highly potent pleu

18 market introduction, spontaneous reports of telithromycin-associated hepatotoxicity, including frank

19 ed to receive 10 days of oral treatment with telithromycin (at a dose of 800 mg daily) or placebo in

20 thromycin, clindamycin, virginiamycin S, and telithromycin bound explain why eubacterial ribosomes co

21 Our structure of the antibiotic telithromycin bound to the T. thermophilus ribosome reve

22 olides 6j and 6k in rats differ from that of telithromycin by having higher lung-to-plasma ratios, la

23 resistance mechanism; (ii) susceptibility to telithromycin can be reliably tested by the agar, microd

24 Telithromycin can cause severe hepatotoxicity.

25 However, the ketolide antibacterial telithromycin consistently demonstrated in vitro activit

26 Telithromycin demonstrated high levels of activity (MIC

27 By disk diffusion with 15-microg telithromycin disks, all strains but one had zones of in

28 al infarction (MI), aripiprazole for MI, and telithromycin for acute liver failure) using Medicaid An

29 nd 1.7+/-1.1 at the end of treatment for the telithromycin group and 2.8+/-1.3 at baseline and 2.0+/-

30 Nausea was more common among patients in the telithromycin group than in the placebo group (P=0.01).

31 The new ketolides cethromycin (ABT-773) and telithromycin have overall antibacterial properties that

32 is study provides evidence of the benefit of telithromycin in patients with acute exacerbations of as

33 controlled study to evaluate the efficacy of telithromycin in patients with acute exacerbations of as

34 nd 6k exhibited better in vivo efficacy than telithromycin in rat lung infection models against Strep

35 m Tracking and Epidemiology for the Ketolide Telithromycin in the United States) surveillance program

36 Telithromycin is a ketolide antibiotic approved by the U

37 Conclusion: Telithromycin is a rare cause of drug-induced liver inju

38 Telithromycin is the first of a new class of ketolide an

39 The results show that (i) telithromycin is very active against erythromycin-suscep

40 By comparison, telithromycin MIC(50)s and MIC(90)s for erythromycin-res

41 Ketolides such as telithromycin mitigate A2058G resistance yet remain susc

42 The frequency of severe telithromycin-related hepatotoxicity cannot be establish

43 of all cases of liver injury associated with telithromycin reported to FDA as of April 2006 by one of

44 The ketolide telithromycin retained activity against all of the isola

45 ractions as well as hydrogen bonding between telithromycin's ARM and U2609.

46 mutation there is significant flexibility in telithromycin's imidazole-pyridine side chain (ARM), ind

47 all organisms were susceptible to a proposed telithromycin susceptibility breakpoint of < or =1 micro

48 y greater reduction among patients receiving telithromycin than among those receiving placebo.

49 ing the macrolide erythromycin, the ketolide telithromycin, the lincosamide clindamycin, and a phenic

50 Within a few days of receiving telithromycin, the patients presented with acute hepatit

51 mpicillin, azithromycin, clarithromycin, and telithromycin was evaluated by altering one variable at

52 Etest MICs of azithromycin and telithromycin were more than twofold higher than agar di

53 evidence also indicates that interactions of telithromycin with the E. coli ribosome more closely res